‘Not What We Expected,’ R&D Industry Says Of ‘Onerous’ EU Paediatric Regulation
Executive Summary
The research-based drug industry has not minced its words in describing the problems it has faced from the EU Paediatric Regulation over the past 10 years.
You may also be interested in...
EU Getting Left Behind On Drug Review Times
Drug review times in the EU are not getting slower but other agencies are getting faster. A pharmaceutical industry representative offers some frank advice on how the EU can stay competitive.
EU Launches Joint Assessment Of Pediatric & Orphan Drugs Legislation
A new European Commission consultation marks the launch of an evaluation exercise to assess the joint impact of the EU pediatric and orphan drugs legislation in supporting the development of pediatric medicines for rare diseases.
EU Action Plan To Address Common Criticisms Of Paediatric Regulation
A wide-range of stakeholders at a European Medicines Agency workshop on how to improve the implementation of the EU Paediatric Regulation offered practical solutions to address the current shortcomings.